1.

Kimura N, Takahashi Y, Shigematsu H, Imai K, Ikeda H, Otani H, Takayama R,Mogami Y, Kimura N, Baba K, Matsuda K, Tottori T, Usui N, Kondou S, Inoue Y.
Risk factors of cognitive impairment in pediatric epilepsy patients with focal cortical2.

dysplasia. Brain Dev 2019; 41: 77-84.
Yamamoto Y, Takahashi Y, Imai K, Ohta A, Kagawa Y, Inoue Y. Prevalence andrisk factors for hyponatremia in adult epilepsy patients: Large-scale cross-sectional
cohort study. Seizure 2019; 73: 26-30.

3.

Yamamoto Y, Takahashi Y, Ikeda H, Imai K, Kagawa Y, Inoue Y. Impact ofCYP2C19 phenotypes on clinical efficacy of stiripentol in Japanese patients withDravet syndrome. Ther Drug Monit 2019 Jul 15.

4.

Yanagishita T, Yamamoto-Shimojima K, Nakano S, Sasaki T, Shigematsu H, ImaiK, Yamamoto T. Phenotypic features of 1q41q42 microdeletion including WDR26
and FBXO28 are clinically recognizable: The first case from Japan. Brain Dev
2019; 41: 452-455.

5.

Yoshitomi S, Ishii A, Koshimizu E, Saitsu H, Imai K, Kato M, Nakashima M,Matsumoto N, Miyatake S, Hirose S, Fujita T, Takahashi Y, Inoue Y. Different
types of suppression-burst patterns in patients with epilepsy of infancy withmigrating focal seizures (EIMFS). Seizure 2019; 65: 118-123.

6.

Yoshitomi S, Takahashi Y, Yamaguchi T, Oboshi T, Horino A, Otani H, Ikeda H,Imai K, Shigematsu H, Inoue Y, Okanishi T, Nakashima M, Matsumoto, YoshimotoJ, Ishii A, Hirose S. Quinidine therapy and therapeutic drug monitoring in four

7.

patients with KCNT1 mutation. Epileptic Disord 2019; 21: 48-54.
Yoshitomi S, Takahashi Y, Yamaguchi T, Imai K, Ishii A, Hirose S, Inoue Y,Efficacy and tolerability of perampanel in pediatric patients with Dravet
syndrome. Epilepsy Res 2019; 154: 34-38.

8.

Takata A, Nakashima M, Saitsu H, Mizuguchi T, Mitsuhashi S, Takahashi Y,
Okamoto N, Osaka H, Nakamura K, Tohyama J, Haginoya K, Takeshita S, Kuki I,
Okanishi T, Goto T, Sasaki M, Sakai Y, Miyake N, Miyatake S, Tsuchida N,Iwama K, Minase G, Sekiguchi F, Fujita A, Imagawa E, Koshimizu E, Uchiyama
Y, Hamanaka K, Ohba C, Itai T, Aoi H, Saida K, Sakaguchi T, Den K, Takahashi
R, Ikeda H, Yamaguchi T, Tsukamoto K, Yoshitomi S, Oboshi T, Imai K, Kimizu T,Kobayashi Y, Kubota M, Kashii H, Baba S, Iai M, Kira R, Hara M, Ohta M, Miyata
Y, Miyata R, Takanashi JI, Matsui J, Yokochi K, Shimono M, Amamoto M,
Takayama R, Hirabayashi S, Aiba K, Matsumoto H, Nabatame S, Shiihara
T, Kato M, Matsumoto N. Comprehensive analysis of coding variants highlights

genetic complexity in developmental and epileptic encephalopathy. Nat Commun
2019; 10: 2506.
9.

Yamamoto T, Imaizumi T, Yamamoto-Shimojima K, Lu Y, Yanagishita T, Shimada
S, Chong PF, Kira R, Ueda R, Ishiyama A, Takeshita E, Momosaki K, Ozasa S,Akiyama T, Kobayashi K, Oomatsu H, Kitahara H, Yamaguchi T, Imai K,
Kurahashi H, Okumura A, Oguni H, Seto T, Okamoto N. Genomic backgrounds ofJapanese patients with undiagnosed neurodevelopmental disorders. Brain Dev
2019; 41: 776-782.

10. Yamamoto T, Shimojima K, Ueda Y, Imai K, Takahashi Y, Imagawa E, Miyake N,Matsumoto N. Independent occurrence of de novo HSPD1 and HIP1 variants inmale brothers with different neurological disorders – leukodystrophy and autism.
Hum Genome Var 2018; 5: 18.
11. Kumada T, Imai K, Takahashi Y, Nabatame S, Oguni H. Ketogenic diet using aJapanese ketogenic milk for patients with epilepsy: A multi-institutional study.
Brain Dev 2018; 40: 188-195.
12. Takayama R, Imai K, Ikeda H, Baba K, Usui N, Takahashi Y, Inoue Y. Successful
hemispherotomy in two refractory epilepsy patients with cerebral hemiatrophyand contralateral EEG abnormalities. Brain Dev 2018; 40: 601-606.
13. Kimizu T, Takahashi Y, Oboshi T, Horino A, Omatsu H, Koike T, Yoshitomi S,Yamaguchi T, Otani H, Ikeda H, Imai K, Shigematsu H, Inoue Y. Chronic
dysfunction of blood-brain barrier in patients with postencephalitic/encephalopathic epilepsy. Seizure 2018; 63: 85-90.
14. Yamamoto Y, Usui N, Nishida T, Mori M, Takahashi Y, Imai K, Kagawa Y, Inoue
Y ． Influence of renal function on pharmacokinetics of antiepileptic drugs
metabolized by CYP3A4 in a patient with renal impairment. Ther Drug Monit 2018;
40: 144-147．
15. Yamamoto Y, Takahashi Y, Horino A, Usui N, Nishida T, Imai K, Kagawa Y, Inoue
Y. Influence of Inflammation on the Pharmacokinetics of Perampanel. Ther Drug
Monit 2018; 40: 725-729.
16. Ikeda H, Imai K, Ikeda H, Matsuda K, Takahashi Y, Inoue Y. Ictal single photonemission computed tomographic study of myoclonic absence seizure. Brain Dev
2018；40: 126-129.

1.

高橋幸利、今井克美、山口解冬、大星大観、池田浩子、吉冨晋作、木水友一、小池敬義、堀野朝子、大松泰生．ケトンフォーミュラの難治てんかん症例における治療効果．脳と発達 2018；50：44-49．
2.

今井克美．ACTH療法、食事療法 - ケトン食などのてんかん食.

Pharma Medica.

2018；36：49-53.
3.

今井克美．Q25 食事療法はどのように行われますか？ 谷口豪、西田拓司、廣實真弓編「てんかん支援 Q&Aーリハビリ・生活支援の実践」p.66-67、医歯薬出版株式会社、東京、2018 年 6 月 1 日発行．